Hemogenyx Pharmaceuticals (LON:HEMO) Shares Climb 5.6% – Here’s Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO) was up 5.6% during mid-day trading on Monday. The company traded as high as GBX 700 and last traded at GBX 695. 19,073 shares traded hands during mid-day trading, a decline of 20% from the average session volume of 23,988 shares. The stock had previously closed at GBX 658.

Hemogenyx Pharmaceuticals Stock Performance

The company has a quick ratio of 6.72, a current ratio of 4.04 and a debt-to-equity ratio of 42.86. The stock has a 50 day simple moving average of GBX 566.94 and a 200 day simple moving average of GBX 692.16. The company has a market capitalization of £47.93 million, a price-to-earnings ratio of -5.31 and a beta of 1.49.

Hemogenyx Pharmaceuticals (LON:HEMO) last posted its earnings results on Monday, September 28th. The company reported GBX (101.70) EPS for the quarter.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.